Eze/Simva Switch Study in Diabetics (0653A-807)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Registration Number
- NCT00541697
- Lead Sponsor
- Organon and Co
- Brief Summary
A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 648
Inclusion Criteria
- Currently being treated with Atorvastatin 10 mg for at least 6 weeks
- Have Type 2 Diabetes
- Weight must be stable for more than 6 weeks before entering the study
Exclusion Criteria
- Consume more than 14 alcoholic drinks per week.
- Pregnant or lactating
- Have taken another investigation drug within 3 months of starting this study
- History of congestive heart failure, heart attack, coronary artery bypass surgery
- Uncontrolled high blood pressure
- HIV positive
- History of cancer in the last 5 years
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Determine the additional LDL-C lowering achieved by switching to MK0653A as compared to Atorvastatin after 6 weeks of treatment 6 Weeks
- Secondary Outcome Measures
Name Time Method Determine the effect of MK0653A versus Atorvastatin on total cholesterol after 6 weeks of treatment 6 Weeks